Aims and Scope of BMC Medicine
BMC Medicine is a peer-reviewed electronic-only medical journal published since 2003 by BioMed Central which is part of Springer Nature. It is described as "the flagship medical journal of the BMC series. An open access, open peer-reviewed general medical journal, BMC Medicine publishes outstanding and influential research in all areas of clinical practice, translational medicine, medical and health advances, public health, global health, policy, and general topics of interest to the biomedical and sociomedical professional communities". Less
Key Metrics
CiteScore 

12.8
Eigenfactor 

0.01 - 0.05
Impact Factor 

5 - 10
Scite Index 

0.87 5-Year SI

SJR 

Q1Medicine (all)

SNIP 

3.18
Recommended pre-submission checks
Powered by 

Topics Covered on BMC Medicine
BMC Medicine Journal Specifications
Indexed in the following public directories
Web of Science
Scopus
DOAJ
SJR
| Overview | |
| Publisher | BMC |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | EUR 3090 | USD 3790 | GBP 2690 |
| Publication Time | 10 |
| Editorial Review Process | Open peer review |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 2003 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC0 |
| OA statement | Visit website |
View less
Planning to publish in BMC Medicine ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in BMC Medicine
Penpulimab in combination with lenalidomide and R-GemOx regimen (R2-GemOx-PD1i) in relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm, phase 2 trial.
- 9 Feb 2026
- BMC medicine
Quantifying lifetime risk for 1,401 infectious diseases across the diabetes spectrum using a Bayesian approach.
- 7 Feb 2026
- BMC medicine
Risk assessment of asthma and allergic rhinitis in atopic dermatitis patients treated with biologics and JAK inhibitors: a systematic review and network meta-analysis of randomized controlled trials.
- 7 Feb 2026
- BMC medicine
Effects of ablation versus drug therapy on clinical outcomes and quality of life by frailty status in atrial fibrillation: a post hoc analysis of the CABANA trial.
- 7 Feb 2026
- BMC medicine
Preclinical activity of brincidofovir in peripheral T-cell and NK/T-cell lymphoma.
- 6 Feb 2026
- BMC medicine
Shared genetic architecture of psychoactive substance use and pan-cancer: insights from a large‑scale genome‑wide cross‑trait analysis.
- 5 Feb 2026
- BMC medicine
Penpulimab in combination with lenalidomide and R-GemOx regimen (R2-GemOx-PD1i) in relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm, phase 2 trial.
- 9 Feb 2026
- BMC medicine
Quantifying lifetime risk for 1,401 infectious diseases across the diabetes spectrum using a Bayesian approach.
- 7 Feb 2026
- BMC medicine
Risk assessment of asthma and allergic rhinitis in atopic dermatitis patients treated with biologics and JAK inhibitors: a systematic review and network meta-analysis of randomized controlled trials.
- 7 Feb 2026
- BMC medicine
Effects of ablation versus drug therapy on clinical outcomes and quality of life by frailty status in atrial fibrillation: a post hoc analysis of the CABANA trial.
- 7 Feb 2026
- BMC medicine
Preclinical activity of brincidofovir in peripheral T-cell and NK/T-cell lymphoma.
- 6 Feb 2026
- BMC medicine
Shared genetic architecture of psychoactive substance use and pan-cancer: insights from a large‑scale genome‑wide cross‑trait analysis.
- 5 Feb 2026
- BMC medicine